Furthermore, combination treatment with s-ASO-g12 and BTZ led to further reduction in tumour volume compared to s-ASO-g12 or BTZ treatment alone (Fig. 7l and Supplementary Fig. 9a, b). The gene discussed is CASC3; the disease is neoplasm.